Health Care [ 8/12 ] | Pharmaceuticals [ 40/73 ]
NASDAQ | Common Stock
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States.
It operates through two segments: Diagnostic Services and Consumer Products.
The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster.
It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease.
In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19.
It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores.
The company was formerly known as The Quigley Corporation.
ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | 0.00 Increased by +100.00% | -0.15 Increased by +100.00% |
| May 7, 25 | -0.13 Decreased by -89.71% | -0.18 Increased by +26.22% |
| Mar 13, 25 | -1.59 Decreased by -211.76% | -0.24 Decreased by -562.50% |
| Nov 7, 24 | -0.35 Decreased by -16.67% | 0.04 Decreased by -975.00% |
| Aug 8, 24 | -0.33 Decreased by -65.00% | -0.24 Decreased by -37.50% |
| May 9, 24 | -0.07 Decreased by -333.33% | -0.28 Increased by +75.00% |
| Mar 15, 24 | -0.51 Decreased by -325.00% | -0.26 Decreased by -96.15% |
| Nov 9, 23 | -0.30 Decreased by -600.00% | -0.19 Decreased by -57.89% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 1.43 M Decreased by -60.62% | 3.97 M Increased by +163.30% | Increased by +277.15% Increased by +260.76% |
| Dec 31, 24 | -2.48 M Decreased by -170.99% | -34.36 M Decreased by -292.63% | Increased by +1.38 K% Increased by +653.06% |
| Sep 30, 24 | 3.15 M Decreased by -62.39% | -6.59 M Decreased by -28.13% | Decreased by -209.38% Decreased by -240.68% |
| Jun 30, 24 | 2.47 M Decreased by -81.28% | -6.15 M Decreased by -78.87% | Decreased by -248.71% Decreased by -855.57% |
| Mar 31, 24 | 3.63 M Decreased by -81.17% | -6.26 M Decreased by -1.24 K% | Decreased by -172.40% Decreased by -6.15 K% |
| Dec 31, 23 | 3.50 M Decreased by -83.97% | -8.75 M Decreased by -258.06% | Decreased by -250.10% Decreased by -2.13 K% |
| Sep 30, 23 | 8.37 M Decreased by -65.43% | -5.14 M Decreased by -631.10% | Decreased by -61.46% Decreased by -1.64 K% |
| Jun 30, 23 | 13.22 M Decreased by -54.57% | -3.44 M Decreased by -146.20% | Decreased by -26.03% Decreased by -201.69% |